#1
#1 out of 1100.00%
health3h ago
Rezolute interim Phase 3 upLIFT data: 6 of 8 meet primary responder criterion; study 50% enrolled
- Interim upLIFT data shows six of eight participants met the primary responder criterion in the open-label Phase 3 trial.
- Study enrollment reached 50% with eight of the planned 16 participants in the Phase 3 trial of ersodetug.
- All six responders achieved complete discontinuation of IV glucose during the 8-week pivotal phase.
- One participant withdrew and later died of cancer progression, counted as a non-responder for the primary endpoint.
- No drug-related adverse events were reported to date in the interim results.
- Topline results are anticipated in the second half of 2026.
- The interim reads come from Rezolute's ongoing open-label Phase 3 trial of ersodetug in tumor HI.
- The source notes the summary is AI-generated and should be verified against the SEC filing.
- Rezolute's stock ticker RZLT is associated with the interim data for upLIFT.
- topline results are expected in H2 2026, indicating near-term milestones for investors.
Vote 0